Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by Closure70on Jan 04, 2019 10:33am
57 Views
Post# 29185970

RE:RE:Stage of development

RE:RE:Stage of developmentBrother, don't know what yoru all about, but easy on the almighty words of wisdom.  Think we have found this boards "captain obvious".  I was soliciting some dialogue on thoughts, your interpretations are only one of a few.  I have been following this and its sister company BLO, like HOUND on that side , market perception drives interest and for those public, price.  So when BNN puts out a feature on Owl, then saying there is NO competition is quite naive.    Only positive, awareness that that detection by breath is a possibility which BTH could use to their advantage if they have some good news to announce.  

BTW, for both companies, serious attention and marketing push would come when they both announce a TSX listing versus CDNX.

If you want to be more helpful, does BTH have a handheld form factor as of yet? I see one in their video's but that doesn't mean its the one.  If so, why wouldn't BLO use a variation of that considering the economies?
Bullboard Posts